Shengqiang Mao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Shengqiang Mao has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Biao Dong
National Clinical Research Center for Geriatrics, Center for Immunology and Hematology and General Practice Ward/International Medical Center Ward, General Practice Medical Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
2 shared publications Dan Du
Advanced Mass Spectrometry Center, Research Core Facility, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, China
2 shared publicationsDan Xie
National Clinical Research Center for Geriatrics, Center for Immunology and Hematology and General Practice Ward/International Medical Center Ward, General Practice Medical Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
2 shared publicationsHai-Ning Chen
Colorectal Cancer Center, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, China
2 shared publications- Heng Xu
Department of Laboratory Medicine/Research Centre of Clinical Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China
2 shared publications - Hong Huang
School of Resources and Environment, Nanchang University, Nanchang 330031, China
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (11) , 2552
Author Correction: Age-, sex- and proximal–distal-resolved multi-omics identifies regulators of intestinal aging in non-human primates
- 6 October 2026
- Published by Springer Nature in Nature Aging
- Vol. 6 (11) , 2552
Open AccessAuthor Correction: Age-, sex- and proximal–distal-resolved multi-omics identifies regulators of intestinal aging in non-human primates
- Open Access
- 1 December 2025
- Published by AIP Publishing in APL Bioengineering
- Vol. 9 (4)
Integration of single-cell and bulk transcriptomics uncovers CHST6 as a shared pathogenic driver in idiopathic pulmonary fibrosis and lung cancer
Idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease, significantly increases the risk of lung cancer, particularly lung adenocarcinoma (LUAD). However, the shared genetic mechanisms driving IPF and LUAD comorbidities remain poorly understood, necessitating integrated multi-omics investigations. Through bulk and single-cell transcriptomic analyses, we identified 308 shared differentially expressed genes enriched in lipid metabolism and immune-inflammatory processes. Additionally, single-cell profiling revealed significant alterations in epithelial cells and macrophage populations between LUAD and IPF tissues, underscoring their role in disease progression. Furthermore, the copy number variation profiling identified a premalignant epithelial subpopulation in IPF exhibiting transcriptional signatures resembling LUAD malignant epithelial cells, and trajectory analysis illustrated a potential temporal progression toward malignancy. To identify co-causal genes, we performed weighted gene coexpression network analysis, defining modules associated with key cell types involved in comorbidities. Moreover, leveraging 101 algorithm combinations across ten machine learning approaches, we constructed a robust prognostic model, pinpointing CHST6 as a top prognostic gene consistently upregulated in both LUAD and IPF. Functional validation confirmed that CHST6 promotes lung cancer cell proliferation, migration, and invasion. In conclusion, our findings elucidate the shared molecular landscape of LUAD and IPF and propose that CHST6 is a promising co-disease therapeutic target.
- 1 December 2025
- Published by AIP Publishing in APL Bioengineering
- Vol. 9 (4)
Open AccessIntegration of single-cell and bulk transcriptomics uncovers CHST6 as a shared pathogenic driver in idiopathic pulmonary fibrosis and lung cancer
Idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease, significantly increases the risk of lung cancer, particularly lung adenocarcinoma (LUAD). However, the shared genetic mechanisms driving IPF and LUAD comorbidities remain poorly understood, necessitating integrated multi-omics investigations. Through bulk and single-cell transcriptomic analyses, we identified 308 shared differentially expressed genes enriched in lipid metabolism and immune-inflammatory processes. Additionally, single-cell profiling revealed significant alterations in epithelial cells and macrophage populations between LUAD and IPF tissues, underscoring their role in disease progression. Furthermore, the copy number variation profiling identified a premalignant epithelial subpopulation in IPF exhibiting transcriptional signatures resembling LUAD malignant epithelial cells, and trajectory analysis illustrated a potential temporal progression toward malignancy. To identify co-causal genes, we performed weighted gene coexpression network analysis, defining modules associated with key cell types involved in comorbidities. Moreover, leveraging 101 algorithm combinations across ten machine learning approaches, we constructed a robust prognostic model, pinpointing CHST6 as a top prognostic gene consistently upregulated in both LUAD and IPF. Functional validation confirmed that CHST6 promotes lung cancer cell proliferation, migration, and invasion. In conclusion, our findings elucidate the shared molecular landscape of LUAD and IPF and propose that CHST6 is a promising co-disease therapeutic target.
- Open Access
- 14 July 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
S100a4+ alveolar macrophages accelerate the progression of precancerous atypical adenomatous hyperplasia by promoting the angiogenic function regulated by fatty acid metabolism
Lung cancer is preceded by premalignant lesions, and what factors drive this transformation and the potential regulatory mode in the context of tumor initiation remain to be elucidated. In the course of precancerous lesions in mice, we found a phasic shift in metabolic patterns. Macrophages are a heterogeneous cell population with high plasticity in the tumor microenvironment. Single-cell interaction and metabolic analyses highlighted a cellular state, S100a4+ alveolar macrophages, which exhibited distinct fatty acid metabolic activity, such as palmitic acid metabolism, at the atypical adenomatous hyperplasia stage, accompanied by an angiogenic-promoting function in a pre-neoplastic setting of mice. These findings were reproducible in human single-cell transcriptomes and had been confirmed by histopathological staining and in vitro cell coculture assays. Taken together, the results from this study demonstrated that the S100a4+ alveolar macrophage subset contributes to tumorigenesis by altering its metabolic state, suggesting that metabolic interventions targeting this cell state in the early stage of disease may delay neoplastic transformation of the lung epithelium.
- 14 July 2025
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Open AccessS100a4+ alveolar macrophages accelerate the progression of precancerous atypical adenomatous hyperplasia by promoting the angiogenic function regulated by fatty acid metabolism
Lung cancer is preceded by premalignant lesions, and what factors drive this transformation and the potential regulatory mode in the context of tumor initiation remain to be elucidated. In the course of precancerous lesions in mice, we found a phasic shift in metabolic patterns. Macrophages are a heterogeneous cell population with high plasticity in the tumor microenvironment. Single-cell interaction and metabolic analyses highlighted a cellular state, S100a4+ alveolar macrophages, which exhibited distinct fatty acid metabolic activity, such as palmitic acid metabolism, at the atypical adenomatous hyperplasia stage, accompanied by an angiogenic-promoting function in a pre-neoplastic setting of mice. These findings were reproducible in human single-cell transcriptomes and had been confirmed by histopathological staining and in vitro cell coculture assays. Taken together, the results from this study demonstrated that the S100a4+ alveolar macrophage subset contributes to tumorigenesis by altering its metabolic state, suggesting that metabolic interventions targeting this cell state in the early stage of disease may delay neoplastic transformation of the lung epithelium.
- Open Access
- 6 February 2024
- Published by Springer Nature in Nature Aging
- Vol. 4 (3) , 414-433
Age-, sex- and proximal–distal-resolved multi-omics identifies regulators of intestinal aging in non-human primates
The incidence of intestinal diseases increases with age, yet the mechanisms governing gut aging and its link to diseases, such as colorectal cancer (CRC), remain elusive. In this study, while considering age, sex and proximal–distal variations, we used a multi-omics approach in non-human primates (Macaca fascicularis) to shed light on the heterogeneity of intestinal aging and identify potential regulators of gut aging. We explored the roles of several regulators, including those from tryptophan metabolism, in intestinal function and lifespan inCaenorhabditis elegans. Suggesting conservation of region specificity, tryptophan metabolism via the kynurenine and serotonin (5-HT) pathways varied between the proximal and distal colon, and, using a mouse colitis model, we observed that distal colitis was more sensitive to 5-HT treatment. Additionally, using proteomics analysis of human CRC samples, we identified links between gut aging and CRC, with high HPX levels predicting poor prognosis in older patients with CRC. Together, this work provides potential targets for preventing gut aging and associated diseases.
- 6 February 2024
- Published by Springer Nature in Nature Aging
- Vol. 4 (3) , 414-433
Open AccessAge-, sex- and proximal–distal-resolved multi-omics identifies regulators of intestinal aging in non-human primates
The incidence of intestinal diseases increases with age, yet the mechanisms governing gut aging and its link to diseases, such as colorectal cancer (CRC), remain elusive. In this study, while considering age, sex and proximal–distal variations, we used a multi-omics approach in non-human primates (Macaca fascicularis) to shed light on the heterogeneity of intestinal aging and identify potential regulators of gut aging. We explored the roles of several regulators, including those from tryptophan metabolism, in intestinal function and lifespan inCaenorhabditis elegans. Suggesting conservation of region specificity, tryptophan metabolism via the kynurenine and serotonin (5-HT) pathways varied between the proximal and distal colon, and, using a mouse colitis model, we observed that distal colitis was more sensitive to 5-HT treatment. Additionally, using proteomics analysis of human CRC samples, we identified links between gut aging and CRC, with high HPX levels predicting poor prognosis in older patients with CRC. Together, this work provides potential targets for preventing gut aging and associated diseases.
- Open Access
- 8 April 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (4) , 1-12
PLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration
Extrachromosomal circular DNAs (eccDNAs) participate in tumorigenesis and tumor progression. However, the role and mechanism of eccDNAs have yet to be elucidated in non-small cell lung cancer (NSCLC). In our research, three surgically matched NSCLC tissue samples, NSCLC cell lines (H1299, A549, and H460), and a normal lung cell line (MRC-5) were used as study objects. High-throughput eccDNA sequencing and bioinformatics analysis were performed to study the distribution pattern and level of eccDNA expression. The upregulated candidate eccDNA-encoding PLCG2 was validated by routine PCR. Plasmid transfection, RNA interference, qRT‒PCR and western blotting experiments were used to verify the expression level of PLCG2. Our results showed that the chromosome distribution, length distribution, and genomic annotation of the eccDNAs were comparable between the NSCLC and normal groups. Nevertheless, there were no significant differences in eccDNAs between NSCLC tissues and matched normal lung tissues. The eccDNA derived from PLCG2 was upregulated in NSCLC cells. TCGA analysis and immunohistochemistry showed that PLCG2 was highly expressed in lung cancer tissues and tended to be associated with poor outcome. We also demonstrated that PLCG2 can promote metastasis through the regulation of mitochondrial respiration. These results suggested that PLCG2 identified by eccDNA sequencing acts as an oncogene and might be a new biomarker for NSCLC diagnosis and prognosis evaluation.
- 8 April 2023
- Published by Springer Nature in Cell Death & Disease
- Vol. 14 (4) , 1-12
Open AccessPLCG2 can exist in eccDNA and contribute to the metastasis of non-small cell lung cancer by regulating mitochondrial respiration
Extrachromosomal circular DNAs (eccDNAs) participate in tumorigenesis and tumor progression. However, the role and mechanism of eccDNAs have yet to be elucidated in non-small cell lung cancer (NSCLC). In our research, three surgically matched NSCLC tissue samples, NSCLC cell lines (H1299, A549, and H460), and a normal lung cell line (MRC-5) were used as study objects. High-throughput eccDNA sequencing and bioinformatics analysis were performed to study the distribution pattern and level of eccDNA expression. The upregulated candidate eccDNA-encoding PLCG2 was validated by routine PCR. Plasmid transfection, RNA interference, qRT‒PCR and western blotting experiments were used to verify the expression level of PLCG2. Our results showed that the chromosome distribution, length distribution, and genomic annotation of the eccDNAs were comparable between the NSCLC and normal groups. Nevertheless, there were no significant differences in eccDNAs between NSCLC tissues and matched normal lung tissues. The eccDNA derived from PLCG2 was upregulated in NSCLC cells. TCGA analysis and immunohistochemistry showed that PLCG2 was highly expressed in lung cancer tissues and tended to be associated with poor outcome. We also demonstrated that PLCG2 can promote metastasis through the regulation of mitochondrial respiration. These results suggested that PLCG2 identified by eccDNA sequencing acts as an oncogene and might be a new biomarker for NSCLC diagnosis and prognosis evaluation.